TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11726255

Group type: EXPERIMENTAL
Intervention: Hypoperfusion-hyperemia (femoral cuff occlusion for 90 seconds at 200 mm Hg followed by 10 seconds of hyperemia)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (40 vertical jumps without femoral artery occlusion)
Number of subjects: 10
Study: 9161740

Group type: EXPERIMENTAL
Intervention: Combination of 2 g propacetamol and 50 mg ketoprofen (group 4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 g propacetamol (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 50 mg ketoprofen (group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 8203367

Group type: EXPERIMENTAL
Intervention: Routine blood flow at 419 mL/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low blood flow at 200 mL/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stop flow technique at 419 mL/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low blood flow technique at 419 mL/min
Number of subjects: 16
Study: 2955955

Group type: EXPERIMENTAL
Intervention: Oxygenated autologous blood perfusion at 60 ml/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control inflations
Number of subjects: 15
Study: 29789919

Group type: EXPERIMENTAL
Intervention: Anterolateral approach to the hip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct lateral approach to the hip
Number of subjects: 0
Study: 27417703

Group type: EXPERIMENTAL
Intervention: Four times daily insulin (q.i.d) regimen
Number of subjects: 480

Group type: COMPARATOR
Intervention: Twice daily insulin (b.i.d) regimen
Number of subjects: 480
Study: 23396509

Group type: EXPERIMENTAL
Intervention: Ribavirin (1000-1200 mg/d) for 4 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy
Number of subjects: 70
Study: 22493916

Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Western medication group (Methylcobalamin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group (within one month after operation)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plum‐blossom needle group (1-3 months after operation)
Number of subjects: 80
Study: 19838812

Group type: COMPARATOR
Intervention: Low SPGI (< 25 microg/l)
Number of subjects: 20928

Group type: COMPARATOR
Intervention: Histologically confirmed atrophic gastritis
Number of subjects: 20928

Group type: EXPERIMENTAL
Intervention: Normal SPGI (>= 25 microg/l)
Number of subjects: 20928

Group type: EXPERIMENTAL
Intervention: Low SPGI
Number of subjects: 20928
Study: 18281262

Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Twin Block (TB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Activator vs Twin Block (TB)
Number of subjects: 50
Study: 15894770

Group type: EXPERIMENTAL
Intervention: Patients with AF and CHF
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Patients with severe LV dysfunction
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: CHF patients with clinical features (with LV dysfunction)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: CHF patients with clinical features (without LV dysfunction)
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Patients with asymptomatic LV dysfunction
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Presence of mitral regurgitation in CHF
Number of subjects: 1321

Group type: EXPERIMENTAL
Intervention: Plasma sP-sel concentrations
Number of subjects: 1321
Study: 12509359

Group type: EXPERIMENTAL
Intervention: Speech recognition technology
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard transcription
Number of subjects: 2
Study: 10378172

Group type: EXPERIMENTAL
Intervention: Writing longhand about a stressful experience
Number of subjects: 80

Group type: COMPARATOR
Intervention: Typing about a stressful experience
Number of subjects: 80

Group type: COMPARATOR
Intervention: Writing longhand about a neutral topic
Number of subjects: 80

Group type: COMPARATOR
Intervention: Typing about a neutral topic
Number of subjects: 80
Study: 8694168

Group type: EXPERIMENTAL
Intervention: Droperidol 1 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Droperidol 0.5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 120
Study: 1654183

Group type: COMPARATOR
Intervention: Vitamins B6 & B12
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hand splint
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Splint combined with vitamins
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Splint combined with injection
Number of subjects: 61
Study: 6671816

Group type: EXPERIMENTAL
Intervention: Yoga program (10 weeks, regular attendance, daily practice for white elders)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study: 31141429

Group type: EXPERIMENTAL
Intervention: RC (2500 Hz, burst 100 Hz, phase duration 200 μs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PC (100 Hz, phase duration 200 μs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RC
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PC
Number of subjects: 27

Group type: COMPARATOR
Intervention: RC and PC
Number of subjects: 27
Study: 31235103

Group type: EXPERIMENTAL
Intervention: Higher intakes of isoleucine, lysine, tyrosine, alanine, threonine, methionine, valine, histidine, aspartic acid, and branched chain, alkaline, and alcoholic amino acids
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Tryptophan, glutamic acid, and acidic amino acids
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Alanine
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Lysine, alanine, methionine, aspartic acid, and alkaline amino acids
Number of subjects: 3881

Group type: EXPERIMENTAL
Intervention: Tryptophan and glutamic acid
Number of subjects: 3881
Study: 28771671

Group type: EXPERIMENTAL
Intervention: Tailored vitamin K dosing regimen (based on index INR and body surface area)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Fixed-dose vitamin K regimen (1 or 2 mg)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Tailored vitamin K dosing regimen
Number of subjects: 181

Group type: COMPARATOR
Intervention: Fixed-dose vitamin K regimen
Number of subjects: 181
Study: 26249766

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysinate (Algidrin® Pediátrico, FARDI S.A.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen base (Dalsy®, Abbott Laboratories S.A.)
Number of subjects: 24
Study: 23816477

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 10151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10151
Study: 22403978

Group type: EXPERIMENTAL
Intervention: 5% nHAP dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% nHAP dentifrice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1100 ppm fluoride dentifrice
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% nHAP dentifrice (control for healthy block)
Number of subjects: 30
Study: 19947259

Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Western medicine (Ibuprofen sustained release capsule)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting group (no treatment)
Number of subjects: 90
Study: 17391568

Group type: EXPERIMENTAL
Intervention: cis-isomer-rich tomato sauce (26.4 mg total lycopene/100 g sauce; 45 % cis-isomers)
Number of subjects: 12

Group type: COMPARATOR
Intervention: all-trans-rich tomato sauce (32.5 mg total lycopene/100 g sauce; 5 % cis-isomers)
Number of subjects: 12
Study: 12504655

Group type: EXPERIMENTAL
Intervention: Complete Response (CR)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Partial Response (PR)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Stable Disease (SD)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Progressive Disease (PD)
Number of subjects: 341
Study: 10977106

Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg, alternate days)
Number of subjects: 22071
Study: 9069587

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 890

Group type: COMPARATOR
Intervention: Oral hypoglycemic agents (OHA)
Number of subjects: 890

Group type: COMPARATOR
Intervention: OHA
Number of subjects: 890
Study: 8444822

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg daily of oral zinc sulphate for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Normal diet introduction
Number of subjects: 26
Study: 3538262

Group type: EXPERIMENTAL
Intervention: Treatment in one stage of the trial
Number of subjects: 741

Group type: COMPARATOR
Intervention: Control treatment in adjacent stage
Number of subjects: 741
Study: 28714343

Group type: EXPERIMENTAL
Intervention: Self-Management and Exercise Group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Educational Group
Number of subjects: 80
Study: 26948484

Group type: EXPERIMENTAL
Intervention: Modified assertive community treatment
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard treatment at community mental health centres
Number of subjects: 521

Group type: COMPARATOR
Intervention: Frequent-stable trajectory
Number of subjects: 521

Group type: COMPARATOR
Intervention: Frequent-increasing trajectory
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: All trajectories
Number of subjects: 521
Study: 25491618

Group type: EXPERIMENTAL
Intervention: Low dose fentanyl (2 mcg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High dose fentanyl (40-70 mcg/kg)
Number of subjects: 100
Study: 21678181

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 87

Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 87
Study: 20070633

Group type: EXPERIMENTAL
Intervention: Educational outreach intervention (PALSA)
Number of subjects: 1999
Study: 18375321

Group type: EXPERIMENTAL
Intervention: 0.02 microg/kg/min of HANP (LH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.05 microg/kg/min of HANP (HH)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal saline solution (SA)
Number of subjects: 45
Study: 15701910

Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily
Number of subjects: 3922

Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose aiming for INR 2.0 to 3.0)
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 3922

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3922

Group type: EXPERIMENTAL
Intervention: Ximelagatran and Warfarin
Number of subjects: 3922
Study: 12787855

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional antipsychotics (CA)
Number of subjects: 182
Study: 10658044

Group type: EXPERIMENTAL
Intervention: Water (3.28 +/- 0.21 liters)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Water + Carbohydrate (3.39 +/- 0.23 liters of solution containing 204 +/- 14 g of carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate (204 +/- 14 g in 0.49 +/- 0.03 liter of solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (0.37 +/- 0.02 liter of water with no carbohydrate)
Number of subjects: 8
Study: 8647574

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1891
Study: 1831248

Group type: EXPERIMENTAL
Intervention: Epidural infusions of sufentanil citrate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Epidural infusions of morphine in 0.5% bupivacaine (MS-MARC)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Switching from initial sufentanil citrate infusions to MS-MARC
Number of subjects: 7
Study: 7117680

Group type: EXPERIMENTAL
Intervention: Meptazinol and hyoscine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Omnopon and hyoscine
Number of subjects: 101
Study: 30776650

Group type: EXPERIMENTAL
Intervention: Roflumilast 100 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roflumilast 250 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roflumilast 1000 μg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30066604

Group type: EXPERIMENTAL
Intervention: Family support interventions targeting family members
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control actions by family members
Number of subjects: 20
Study: 26655562

Group type: EXPERIMENTAL
Intervention: Face-to-face nursing interventions
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Entrance interview
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Full model of predictors
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Entrance interview (strongest predictor)
Number of subjects: 104
Study: 25532088

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fascia iliaca compartment block (FIC)
Number of subjects: 60
Study: 22247360

Group type: EXPERIMENTAL
Intervention: Intensive treatment with conventional combination therapy for 24 months
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Simplified remission score based on age, sex, and tender joint count (TJC)
Number of subjects: 378
Study: 19201183

Group type: EXPERIMENTAL
Intervention: Lutein-fortified fermented milk (high content, 16 mg lutein)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lutein-fortified fermented milk (low content, 8 mg lutein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: In vitro assessment of lutein ester hydrolysis
Number of subjects: 24
Study: 17391579

Group type: EXPERIMENTAL
Intervention: Formal multifaceted sedation course (4-hour duration)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Self-directed learning (no formal teaching)
Number of subjects: 48
Study: 16326293

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate, 2 g/70 kg, infused intravenously during and for 3 days postoperatively
Number of subjects: 150

Group type: COMPARATOR
Intervention: Codeine, 60 mg/70 kg, given orally 4 times a day for 3 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diclofenac sodium, 75 mg, given orally twice a day for 3 days
Number of subjects: 150
Study: 11983638

Group type: EXPERIMENTAL
Intervention: Brief group dynamic psychotherapy (BGDP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clinical management (control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: BGDP
Number of subjects: 83
Study: 9617980

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg twice a day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5-75 mg twice a day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mianserin (10-20 mg three times a day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7696059

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1 MAC of end‐tidal isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypoxia alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypoxia with isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypoxia with domperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypoxia with isoflurane and domperidone
Number of subjects: 20
Study: 1978500

Group type: EXPERIMENTAL
Intervention: Remoxipride (150-600 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Haloperidol (5-45 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 9

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 9
Study: 7017492

Group type: EXPERIMENTAL
Intervention: Broncaspin suspension (3 tablespoonfuls a day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Recognised commercial preparation (3 tablespoonfuls a day)
Number of subjects: 15
Study: 31127612

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DBT-A with more than 3 months follow-up treatment
Number of subjects: 92
Study: 27655859

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study: 26126161

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 412

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 412
Study: 25194079

Group type: EXPERIMENTAL
Intervention: tolterodine plus intermittent percutaneous needle sacral nerve stimulation (IPN‐SNS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: tolterodine only
Number of subjects: 240
Study: 21107287

Group type: EXPERIMENTAL
Intervention: Cisplatin/Vinorelbine
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel
Number of subjects: 616

Group type: COMPARATOR
Intervention: Younger patient cohort
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Toxicity parameters
Number of subjects: 616
Study: 19844234

Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy (1500 mg once daily)
Number of subjects: 100
Study: 17537071

Group type: EXPERIMENTAL
Intervention: Conjoint family therapy (CFT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Separated family therapy (SFT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CFT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SFT
Number of subjects: 40
Study: 17142202

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + HCTZ 12.5 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Olmesartan 20 mg + HCTZ 12.5 mg
Number of subjects: 130
Study: 12661796

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 10547169

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 300
Study: 8852310

Group type: EXPERIMENTAL
Intervention: Centroid method (study group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional method (control group)
Number of subjects: 10
Study: 1991894

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 307

Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 307
Study: 6346348

Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29777663

Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (ENG)
Number of subjects: 2963

Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant (LNG)
Number of subjects: 2963

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 2963
Study: 27110107

Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 28
Study: 25722221

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day) plus Metformin (850 mg twice daily after meals)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg/day) plus Placebo
Number of subjects: 37
Study: 24325472

Group type: EXPERIMENTAL
Intervention: High n-3 PUFA meal (0.97 n-6/n-3 ratio)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low n-3 PUFA meal (8.80 n-6/n-3 ratio)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia group (HTG)
Number of subjects: 16
Study: 19949016

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise program (n = 29)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (n = 28)
Number of subjects: 57
Study: 19014306

Group type: EXPERIMENTAL
Intervention: Outpatient treatments for depression
Number of subjects: 103
Study: 15961289

Group type: EXPERIMENTAL
Intervention: Written instructions in addition to verbal instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal instructions only (Control)
Number of subjects: 0
Study: 12734019

Group type: EXPERIMENTAL
Intervention: Novel approach using randomization distribution to compute anticipated maximum bias
Number of subjects: 0
Study: 11284461

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500 mg/day, adjustable after 1-3 days)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 8670663

Group type: EXPERIMENTAL
Intervention: Retinotopic mapping strategies using magnetic recordings of brain activity and anatomical MRI
Number of subjects: 0
Study: 1931405

Group type: EXPERIMENTAL
Intervention: Continuous spinal block (T4-S5)
Number of subjects: 21

Group type: COMPARATOR
Intervention: General anaesthesia (Control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Extradural block (T4-S5)
Number of subjects: 21
Study: 7049592

Group type: EXPERIMENTAL
Intervention: Amcinonide ointment 0.1 percent twice a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05 percent three times a day
Number of subjects: 50
Study: 31647691

Group type: EXPERIMENTAL
Intervention: Navigation help
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no navigation help)
Number of subjects: 0
Study: 30604559

Group type: EXPERIMENTAL
Intervention: Serelaxin + Standard of Care (SoC)
Number of subjects: 2666

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 2666
Study: 28468770

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400,000 IU oral vitamin D3, with an additional 200,000 IU if serum 25(OH)D was <100 nmol/L after 4 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 62
Study: 26042485

Group type: EXPERIMENTAL
Intervention: BF Spiromax 160/4.5 μg
Number of subjects: 90

Group type: COMPARATOR
Intervention: BF Turbohaler 200/6 μg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BF Spiromax 320/9 μg
Number of subjects: 90

Group type: COMPARATOR
Intervention: BF Turbohaler 400/12 μg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BF Spiromax (±charcoal block)
Number of subjects: 90

Group type: COMPARATOR
Intervention: BF Turbohaler (±charcoal block)
Number of subjects: 90